| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(2 years ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8106029 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(4 years ago) | |
| US7683037 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(4 years ago) | |
| US8536150 | ASTELLAS | Methods of myocardial perfusion imaging |
Jun, 2019
(4 years ago) | |
| US8470801 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(4 years ago) | |
| US7655636 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(4 years ago) | |
| US7582617 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(4 years ago) | |
| US9289446 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(4 years ago) | |
| US9045519 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| US7183264 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) | |
| US8183226 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(4 years ago) | |
| US8133879 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(4 years ago) | |
| US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(2 years from now) | |
Lexiscan is owned by Astellas.
Lexiscan contains Regadenoson.
Lexiscan has a total of 19 drug patents out of which 16 drug patents have expired.
Expired drug patents of Lexiscan are:
- US8106029
- US7683037
- US8536150
- US8470801
- US7655636
- US7582617
- US9289446
- US9045519
- US7183264
- US8183226
- US8133879
- US7655637
- US6642210
- US7144872
- USRE47351
- US6403567
Lexiscan was authorised for market use on 10 April, 2008.
Lexiscan is available in solution;intravenous dosage forms.
Lexiscan can be used as method of myocardial imaging, a method of myocardial perfusion imaging and increasing coronary blood flow, method for stimulating coronary vasodilation for purposes of imaging the heart.
Drug patent challenges can be filed against Lexiscan from 10 April, 2012.
The generics of Lexiscan are possible to be released after 02 February, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-194) | Jan 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart; Method of myocardial imaging; A method of myocardial perfusion imaging and increasing coronary blood flow
Dosage: SOLUTION;INTRAVENOUS
LEXISCAN family patents
